Sunitinib Shows Promise After Immunotherapy Failure in Kidney Cancer

The treatment landscape for metastatic renal cell carcinoma has shifted dramatically over the past decade. Anti-angiogenic agents like sunitinib were once the cornerstone of first-line therapy, but the emergence of immune checkpoint inhibitor combinations has repositioned them further down the treatment algorithm. This creates a clinically urgent question: do these older targeted agents still work after a patient's cancer has become resistant to immunotherapy?

This phase II trial, sponsored by the Spanish Oncology Genito-Urinary Group, was designed to directly address that gap. The study enrolled 23 patients with clear cell renal carcinoma who had received and progressed on first-line immunotherapy-based regimens being evaluated in concurrent phase III trials. All patients then received sunitinib as their next line of treatment.

The scientific rationale is sound. Sunitinib had previously demonstrated efficacy in patients who failed cytokine-based therapies, suggesting its mechanism — blocking tumor blood vessel formation via VEGF receptor inhibition — may remain relevant regardless of prior immunotherapy exposure. Immune checkpoint resistance does not necessarily confer cross-resistance to anti-angiogenic pathways.

The trial ran from May 2017 to September 2020 and has since been completed. With an enrollment of just 23 patients, the study is exploratory rather than definitive, but it provides a critical early signal for a patient population that was largely unstudied at the time of design.

For clinicians managing metastatic kidney cancer today, this data matters. As checkpoint inhibitor combinations — including PD-1/PD-L1 and CTLA-4 targeted regimens — become standard first-line care, the sequencing of subsequent therapies becomes increasingly important. Understanding whether sunitinib retains efficacy post-immunotherapy could meaningfully influence treatment planning and patient outcomes across a growing population of refractory cases.